{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T21:39:08Z","timestamp":1791149948045,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1124\/jpet.111.181321","type":"journal-article","created":{"date-parts":[[2011,4,29]],"date-time":"2011-04-29T02:21:09Z","timestamp":1304043669000},"page":"412-420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["The Antithrombotic Activity of EP224283, a Neutralizable Dual Factor Xa Inhibitor\/Glycoprotein IIbIIIa Antagonist, Exceeds That of the Coadministered Parent Compounds"],"prefix":"10.1016","volume":"338","author":[{"given":"B\u00e9atrice","family":"Hechler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Freund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghina","family":"Alame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Leguay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Gaertner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Cazenave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Petitou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gachet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.111.181321_bib1","doi-asserted-by":"crossref","first-page":"40A","DOI":"10.1016\/j.amjcard.2008.11.023","article-title":"Advances in antiplatelet therapy: agents in clinical development","volume":"103","author":"Angiolillo","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1124\/jpet.111.181321_bib2","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/clpt.1994.152","article-title":"Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb\/IIIa receptor antagonist, in healthy men","volume":"56","author":"Barrett","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.111.181321_bib3","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1056\/NEJMp0806848","article-title":"Prasugrel in clinical practice","volume":"361","author":"Bhatt","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.111.181321_bib4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/BF03256588","article-title":"Fondaparinux sodium: a review of its use in the management of acute coronary syndromes","volume":"8","author":"Blick","year":"2008","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1124\/jpet.111.181321_bib5","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.jacc.2009.03.083","article-title":"Antithrombotics in acute coronary syndromes","volume":"54","author":"Bonaca","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/jpet.111.181321_bib6","first-page":"13","article-title":"Preparation of washed platelet suspensions from human and rodent blood","volume":"272","author":"Cazenave","year":"2004","journal-title":"Methods Mol Biol"},{"key":"10.1124\/jpet.111.181321_bib7","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1055\/s-0037-1613739","article-title":"Murine thrombosis models","volume":"92","author":"Day","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1124\/jpet.111.181321_bib8","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.amjcard.2009.01.349","article-title":"Balancing myocardial ischemic and bleeding risks in patients with non-ST-segment elevation myocardial infarction","volume":"103","author":"D\u00edez","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1124\/jpet.111.181321_bib9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0022-3565(25)33551-2","article-title":"Mouse antithrombotic assay: a simple method for the evaluation of antithrombotic agents in vivo. Potentiation of antithrombotic activity by ethyl alcohol","volume":"225","author":"DiMinno","year":"1983","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.181321_bib10","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.1538-7836.2011.04218.x","article-title":"Mechanisms underlying FeCl3-induced arterial thrombosis","volume":"9","author":"Eckly","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1124\/jpet.111.181321_bib11","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1160\/TH09-08-0555","article-title":"Development of idraparinux and idrabiotaparinux for anticoagulant therapy","volume":"102","author":"Harenberg","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1124\/jpet.111.181321_bib12","doi-asserted-by":"crossref","DOI":"10.1160\/THS10-11-0730","article-title":"Comparison of two murine models of thrombosis induced by atherosclerotic plaque injury","author":"Hechler","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1124\/jpet.111.181321_bib13","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1124\/jpet.105.094037","article-title":"MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2\u2032-deoxyadenosine-3\u2032,5\u2032-bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in mice","volume":"316","author":"Hechler","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.181321_bib14","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1182\/blood.V91.11.4197","article-title":"Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide","volume":"91","author":"Herbert","year":"1998","journal-title":"Blood"},{"key":"10.1124\/jpet.111.181321_bib15","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0049-3848(90)90106-M","article-title":"Rat model of arterial thrombosis induced by ferric chloride","volume":"60","author":"Kurz","year":"1990","journal-title":"Thromb Res"},{"key":"10.1124\/jpet.111.181321_bib16","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1016\/j.jacc.2009.10.015","volume":"54","author":"Kushner","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/jpet.111.181321_bib17","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1182\/blood-2007-03-080184","article-title":"Megakaryocyte-restricted MYH9 inactivation dramatically affects hemostasis while preserving platelet aggregation and secretion","volume":"110","author":"L\u00e9on","year":"2007","journal-title":"Blood"},{"key":"10.1124\/jpet.111.181321_bib18","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1161\/01.CIR.103.5.718","article-title":"Key role of the P2Y(1) receptor in tissue factor-induced thrombin-dependent acute thromboembolism: studies in P2Y(1)-knockout mice and mice treated with a P2Y(1) antagonist","volume":"103","author":"L\u00e9on","year":"2001","journal-title":"Circulation"},{"key":"10.1124\/jpet.111.181321_bib19","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1172\/JCI8399","article-title":"Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice","volume":"104","author":"L\u00e9on","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.111.181321_bib20","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1365-2796.2008.01965.x","article-title":"The molecular mechanisms of the thrombotic complications of atherosclerosis","volume":"263","author":"Libby","year":"2008","journal-title":"J Intern Med"},{"key":"10.1124\/jpet.111.181321_bib21","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nature06797","article-title":"Triggers, targets and treatments for thrombosis","volume":"451","author":"Mackman","year":"2008","journal-title":"Nature"},{"key":"10.1124\/jpet.111.181321_bib22","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nrd2957","article-title":"Antiplatelet therapies for the treatment of cardiovascular disease","volume":"9","author":"Michelson","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/jpet.111.181321_bib23","doi-asserted-by":"crossref","first-page":"199S","DOI":"10.1378\/chest.08-0672","article-title":"Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Patrono","year":"2008","journal-title":"Chest"},{"key":"10.1124\/jpet.111.181321_bib24","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1182\/blood-2002-06-1847","article-title":"Role of the intracellular domains of GPIb in controlling the adhesive properties of the platelet GPIb\/V\/IX complex","volume":"101","author":"Perrault","year":"2003","journal-title":"Blood"},{"key":"10.1124\/jpet.111.181321_bib25","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1002\/anie.200300640","article-title":"A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next?","volume":"43","author":"Petitou","year":"2004","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1124\/jpet.111.181321_bib26","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1517\/13543784.17.5.773","article-title":"Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders","volume":"17","author":"Prandoni","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1124\/jpet.111.181321_bib27","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cpcardiol.2009.11.002","article-title":"Antiplatelet agents in acute coronary syndromes","volume":"35","author":"Sakhuja","year":"2010","journal-title":"Curr Probl Cardiol"},{"key":"10.1124\/jpet.111.181321_bib28","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1111\/j.1538-7836.2008.03089.x","article-title":"Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy","volume":"6","author":"Savi","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1124\/jpet.111.181321_bib29","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1538-7836.2010.03737.x","article-title":"Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding","volume":"8","author":"Schulman","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1124\/jpet.111.181321_bib30","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1161\/ATVBAHA.107.142810","article-title":"Murine models of vascular thrombosis (Eitzman series)","volume":"27","author":"Westrick","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524464732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524464732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.111.181321","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T02:33:03Z","timestamp":1740018783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524464732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0022356524464732"],"URL":"https:\/\/doi.org\/10.1124\/jpet.111.181321","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Antithrombotic Activity of EP224283, a Neutralizable Dual Factor Xa Inhibitor\/Glycoprotein IIbIIIa Antagonist, Exceeds That of the Coadministered Parent Compounds","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.111.181321","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2011 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}